机构名称：
¥ 1.0
The Chair welcomed Dr Susan McGeoch, Consultant Physician, Diabetes, Endocrine and General Medicine, to the meeting to talk about the pharmacological management of Type 2 diabetes mellitus (T2DM), including the request for tirzepatide (item 5.1), formulary choice glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and other antidiabetic medicines for T2DM (item 6.1）。McGeoch博士分享了包括Tirzepatide在内的T2DM药理学管理的本地最新草案指南。McGeoch博士指出，随着时间的流逝，T2DM的药理学管理随着更多的药物而变得更加复杂。McGeoch博士确认：•专业服务支持Grampian的初级保健同事提供区域性糖尿病护理•NHS Grampian中有约33,000人患有糖尿病患者，87-89％的糖尿病具有T2DM，目前在当地提供了糖尿病的指导（2022222222） guidance expected • locally tirzepatide would be considered a fourth-line alternative, after the injectable GLP-1 RAs • there have been significant problems with shortages of GLP-1 RAs • NICE has positioned the GLP-1 RAs further down the pathway as they are one of the more expensive agents • [injectable] liraglutide and semaglutide have good cardiovascular data
2024年6月18日，星期二，格式小组会议
主要关键词
相关文件推荐
